Aligos Therapeutics, Inc. General and Administrative Expense
Aligos Therapeutics, Inc. (ALGS) reported General and Administrative Expense of $5.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-06
- Aligos Therapeutics, Inc. general and administrative expense for the quarter ending 2026-06-30 was $5.62M, a 1.12% increase year-over-year.
- Aligos Therapeutics, Inc. general and administrative expense for the quarter ending 2026-03-31 was $6.41M, a 26.82% increase year-over-year.
- Aligos Therapeutics, Inc. general and administrative expense for the quarter ending 2025-12-31 was $4.95M, a 4.19% decline year-over-year.
- Aligos Therapeutics, Inc. general and administrative expense for the quarter ending 2025-09-30 was $5.17M, a 11.65% increase year-over-year.
- Aligos Therapeutics, Inc. general and administrative expense for fiscal 2025 was $20.72M, a 9.25% decline from fiscal 2024.
- Aligos Therapeutics, Inc. general and administrative expense for fiscal 2024 was $22.83M, a 25.43% decline from fiscal 2023.
- Aligos Therapeutics, Inc. general and administrative expense for fiscal 2023 was $30.62M, a 15.93% increase from fiscal 2022.
- Aligos Therapeutics, Inc. general and administrative expense for fiscal 2022 was $26.41M, a 7.42% decline from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.62M 10-Q · filed 2026-08-06 | $12.03M 10-Q · filed 2026-08-06 | $16.97M derived: sum of 3 quarters · filed 2026-08-06 | $22.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.41M 10-Q · filed 2026-05-07 | $11.35M derived: sum of 2 quarters · filed 2026-05-07 | $16.52M derived: sum of 3 quarters · filed 2026-05-07 | $22.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.11M derived: sum of 2 quarters · filed 2026-03-05 | $15.67M derived: sum of 3 quarters · filed 2026-08-06 | $20.72M 10-K · filed 2026-03-05 |
| 2025-09-30 | $5.17M 10-Q · filed 2025-11-06 | $10.72M derived: sum of 2 quarters · filed 2026-08-06 | $15.77M 10-Q · filed 2025-11-06 | $20.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.56M 10-Q · filed 2026-08-06 | $10.61M 10-Q · filed 2026-08-06 | $15.77M derived: sum of 3 quarters · filed 2026-08-06 | $20.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.05M 10-Q · filed 2026-05-07 | $10.21M derived: sum of 2 quarters · filed 2026-05-07 | $14.84M derived: sum of 3 quarters · filed 2026-05-07 | $21.21M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.79M derived: sum of 2 quarters · filed 2026-03-05 | $16.16M derived: sum of 3 quarters · filed 2026-03-05 | $22.83M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.63M 10-Q · filed 2025-11-06 | $11.00M derived: sum of 2 quarters · filed 2025-11-06 | $17.67M 10-Q · filed 2025-11-06 | $24.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.38M 10-Q · filed 2025-08-06 | $13.04M 10-Q · filed 2025-08-06 | $19.46M derived: sum of 3 quarters · filed 2025-08-06 | $25.91M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $6.67M 10-Q · filed 2025-05-06 | $13.09M derived: sum of 2 quarters · filed 2025-05-06 | $19.53M derived: sum of 3 quarters · filed 2025-05-06 | $28.78M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $6.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $12.86M derived: sum of 2 quarters · filed 2025-03-10 | $22.11M derived: sum of 3 quarters · filed 2025-03-10 | $30.62M 10-K · filed 2025-03-10 |
| 2023-09-30 | $6.44M 10-Q · filed 2024-11-06 | $15.69M derived: sum of 2 quarters · filed 2024-11-06 | $24.20M 10-Q · filed 2024-11-06 | $31.31M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $9.25M 10-Q · filed 2024-08-06 | $17.75M 10-Q · filed 2024-08-06 | $24.87M derived: sum of 3 quarters · filed 2024-08-06 | $30.13M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $8.51M 10-Q · filed 2024-05-07 | $15.63M derived: sum of 2 quarters · filed 2024-05-07 | $20.89M derived: sum of 3 quarters · filed 2024-05-07 | $28.46M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $12.38M derived: sum of 2 quarters · filed 2024-03-12 | $19.96M derived: sum of 3 quarters · filed 2024-03-12 | $26.41M 10-K · filed 2024-03-12 |
| 2022-09-30 | $5.26M 10-Q · filed 2023-11-02 | $12.84M derived: sum of 2 quarters · filed 2023-11-02 | $19.29M 10-Q · filed 2023-11-02 | $29.01M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $7.58M 10-Q · filed 2023-08-03 | $14.03M 10-Q · filed 2023-08-03 | $23.75M derived: sum of 3 quarters · filed 2023-08-03 | $30.22M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $6.45M 10-Q · filed 2023-05-04 | $16.17M derived: sum of 2 quarters · filed 2023-05-04 | $22.64M derived: sum of 3 quarters · filed 2023-05-04 | $29.20M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $16.19M derived: sum of 2 quarters · filed 2023-03-09 | $22.75M derived: sum of 3 quarters · filed 2023-03-09 | $28.53M 10-K · filed 2023-03-09 |
| 2021-09-30 | $6.47M 10-Q · filed 2022-11-02 | $13.03M derived: sum of 2 quarters · filed 2022-11-02 | $18.81M 10-Q · filed 2022-11-02 | $25.02M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $6.56M 10-Q · filed 2022-08-04 | $12.34M 10-Q · filed 2022-08-04 | $18.54M derived: sum of 3 quarters · filed 2022-08-04 | $22.77M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $5.78M 10-Q · filed 2022-05-04 | $11.99M derived: sum of 2 quarters · filed 2022-05-04 | $16.21M derived: sum of 3 quarters · filed 2022-05-04 | $20.31M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $10.43M derived: sum of 2 quarters · filed 2022-03-10 | $14.53M derived: sum of 3 quarters · filed 2022-03-10 | $17.94M 10-K · filed 2022-03-10 |
| 2020-09-30 | $4.22M 10-Q · filed 2021-11-04 | $8.32M derived: sum of 2 quarters · filed 2021-11-04 | $11.74M 10-Q · filed 2021-11-04 | $15.20M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $4.09M 10-Q · filed 2021-08-05 | $7.51M 10-Q · filed 2021-08-05 | $10.98M derived: sum of 3 quarters · filed 2021-08-05 | $13.75M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $3.42M 10-Q · filed 2021-05-10 | $6.88M derived: sum of 2 quarters · filed 2021-05-10 | $9.66M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $6.24M derived: sum of 2 quarters · filed 2021-03-23 | $10.01M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $2.77M 10-Q · filed 2020-11-25 | $6.54M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |